Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06728410 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
A Phase 2 study of Intrahepatic Cholangiocarcinoma and FGFR2 Gene Mutation, sponsored by Mehmet Akce.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT06728410 is a Phase 2 study of Intrahepatic Cholangiocarcinoma and FGFR2 Gene Mutation that is actively recruiting participants, run by Mehmet Akce. The registered enrollment target is 38 participants, below the 133-participant average among 17 other Intrahepatic Cholangiocarcinoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06728410, a Phase 2 study of Intrahepatic Cholangiocarcinoma and FGFR2 Gene Mutation, is actively recruiting participants, sponsored by Mehmet Akce.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single arm phase II study of pemigatinib and durvalumab combination in patients with FGFR-2 fusion or rearrangement positive intrahepatic cholangiocarcinoma. Each cycle will be 3 weeks. Pemigatinib is administered at 13.5 mg orally daily 2 weeks on and 1 week off. Durvalumab is administered at 1500 mg intravenously once every 3 weeks. Subjects will require a visit with appropriate laboratory work prior to the start of each cycle. Disease assessment will occur every 9 weeks. Subjects will continue treatment until progression per RECIST 1.1, toxicity or subject/physician decision. A maximum of 24 months (about 35 cycles) of pemigatinib and durvalumab treatment from Cycle 1 Day 1 is allowed.
Conditions Studied
Interventions
- DRUG Durvalumab
- DRUG Pemigatinib
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2026-01-27 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06728410
The ClinicalTrials.gov registry entry for NCT06728410 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 133-participant average among 17 other Intrahepatic Cholangiocarcinoma trials with a reported enrollment target (71% lower). The listed sponsor is Mehmet Akce, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Intrahepatic Cholangiocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Durvalumab is the first listed.
NCT06728410 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT06728410 about?
NCT06728410 is a clinical study titled "A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement". This is a single arm phase II study of pemigatinib and durvalumab combination in patients with FGFR-2 fusion or rearrangement positive intrahepatic cholangiocarcinoma. Each cycle will be 3 weeks. Pemigatinib is administered at 13.5 mg orally daily 2 weeks on and 1 week off. Durvalumab is administere...
What is the current status of trial NCT06728410?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2026-01-27. Estimated completion is 2027-07.
What conditions does trial NCT06728410 study?
This clinical trial studies the following conditions: Intrahepatic Cholangiocarcinoma, FGFR2 Gene Mutation, FGFR2 Gene Rearrangement.
What interventions are being tested in trial NCT06728410?
The interventions under investigation include: Durvalumab (DRUG), Pemigatinib (DRUG).
Who is sponsoring clinical trial NCT06728410?
This trial is sponsored by Mehmet Akce, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06728410 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intrahepatic Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer
RECRUITING · Phase 2
-
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
RECRUITING · Phase 2
-
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
RECRUITING · Phase 2
-
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
RECRUITING · Phase 2
-
Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
RECRUITING · Phase 2
-
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.